Truist Securities Maintains Buy on Immunome, Raises Price Target to $38
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price target from $37 to $38.
Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price target from $37 to $38.